GCM
FATE icon

Goldstream Capital Management’s Fate Therapeutics FATE Stock Holding History

Goldstream Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-42,225
Closed -$2.47M – 28
2021
Q4 		$2.47M Buy
+42,225
New +$2.39M 0.61% 18

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Goldstream Capital Management's FATE Position: Q1 2022 in Review

Goldstream Capital Management sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 42,225 shares — an estimated $2.47M sold.

Goldstream Capital Management first reported a position in FATE in Q4 2021 and held it in 1 quarter. The position peaked at $2.47M in Q4 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Goldstream Capital Management reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Goldstream Capital Management sold 42,225 Fate Therapeutics shares in Q1 2022, an estimated $2.47M.
  • Goldstream Capital Management first reported a position in Fate Therapeutics in Q4 2021 and held it in 1 quarter.
  • Goldstream Capital Management's Fate Therapeutics position peaked at $2.47M in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Goldstream Capital Management's 13F filing for Q1 2022, filed 13 May 2022.